PharmiWeb.com - Global Pharma News & Resources

General - Press Releases

Date Title Company
07-Dec-2023 Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City Businesswire
07-Dec-2023 Validation Data on a Novel Prognostic Test Developed by GRAIL in Stage I Lung Cancer Presented at North America Conference on Lung Cancer Businesswire
06-Dec-2023 Celiac Disease Foundation Teams Up with Mark Cuban Cost Plus Drug Company Businesswire
06-Dec-2023 Parker Health Announces the Appointment of Dr. Tushar Hazra as Chief Technology Officer, and Other Key Executive Personnel Businesswire
06-Dec-2023 Global Positive Airway Pressure Devices Pipeline Analysis Report 2023: Stages of Development, Segments, Region, Regulatory Path and Key Companies - ResearchAndMarkets.com Businesswire
06-Dec-2023 Kubota Vision Announces Agreement with AUROLAB for Development, Manufacturing, Supply, and Distribution License of eyeMO Businesswire
06-Dec-2023 Kubota Vision Announces Vendor Agreement with IQVIA for eyeMO Businesswire
06-Dec-2023 Neue Post-Hoc-Analyse von Phase-3-Daten zeigt, dass AJOVY® (Fremanezumab) Migräneattacken bei Erwachsenen mit Migräne und komorbider Adipositas reduziert Businesswire
06-Dec-2023 BioStar Capital Closes Fund V at $130.3 Million, Surpassing Previous Funds Businesswire
06-Dec-2023 ThreatNG Launches Groundbreaking Open-Source Governance and Compliance Dataset Project Businesswire
06-Dec-2023 Lubrizol’s 2023 Innovations Advanced Mobility, Improved Wellbeing and Enhanced Modern Life Businesswire
06-Dec-2023 Schwarzman Scholars Announces Class of 2024-2025 Businesswire
06-Dec-2023 BioAlberta Announces Partnership with Lawcubator Technologies Businesswire
06-Dec-2023 Global Abdominal Drainage Tubes Strategic Research Report 2023 - ResearchAndMarkets.com Businesswire
06-Dec-2023 Taiwan Bio and TRACT Therapeutics, Inc. Announce Strategic Partnership to Advance a Novel Therapeutic Approach for Preventing Rejection in Solid Organ Transplant Businesswire
06-Dec-2023 Une nouvelle analyse post hoc des données de phase 3 montre qu’AJOVY® (fremanezumab) réduit les crises de migraine chez les adultes souffrant de migraine et d’obésité comorbide Businesswire
06-Dec-2023 MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis Businesswire
06-Dec-2023 Catawba Research Partners With Elligo Health Research® to Expand Access and Simplify Clinical Research Participation Businesswire
06-Dec-2023 Riassunto: Una nuova analisi a posteriori dei dati di fase 3 dimostra come AJOVY® (fremanezumab) consenta di ridurre gli attacchi di emicrania in adulti soggetti ad emicranie e con obesità come comorbilità Businesswire
06-Dec-2023 bit.bio further expands ioCells™️ range with early access launch of ioMotor Neurons™️ for research and drug discovery in diseases such as amyotrophic lateral sclerosis (ALS) Businesswire